Navigation Links
Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
Date:9/17/2008

HAMPTON, Va., Sept. 17 /PRNewswire/ -- Keraderm, a leader in the development of phototherapy treatments for infections, plans to introduce a $100 phototherapy treatment for fungal nail infections (onychomycosis) in 2009 upon completion of their current pivotal trials and pending marketing clearance from the FDA.

"Our goal," states Keraderm CEO Bill Cumbie, "is to develop a safe and effective treatment for onychomycosis that can be accessed by a large number of people at a low cost. Many people cannot use current medications due to their high cost, significant side effects, and contraindications while taking other medications. Our pilot clinical trials have indicated the efficacy of the best oral medications with no significant side effects. We will establish the safety and efficacy of our treatment with our current pivotal clinical trials which will be submitted to the FDA for approval as the first phototherapy treatment for onychomycosis. The beauty of our treatment is that it can be delivered easily and inexpensively. We hope to introduce our treatment in 2009 at $100 for several treatments and continue to improve the technology so that eventually only one treatment in the $100 range will be necessary. We are also working to establish insurance reimbursement for our therapy which will further reduce cost to the consumer."

Keraderm is well on the way to being the first phototherapy treatment approved by the FDA for onychomycosis with its research published in the prestigious peer-reviewed British Journal of Dermatology and presented at the 2007 World Congress of Dermatology and the 2008 Annual Conference of the American Academy of Dermatology. Keraderm also has a growing portfolio of national and international patents that protect the key aspects of its proprietary platform technology to treat infections.

About Keraderm

Keraderm LLC is a medical device company with proprietary, patented, platform technology for a wide variety of infections. This technology has the potential to effectively treat infections without the serious side effects that many medications have and to effectively treat infections caused by drug resistant organisms such as MRSA. Keraderm has obtained patents on its key technologies to treat infections and has a number of additional patent applications pending on refinements of its technology. Published laboratory and clinical studies indicate that the technology has great potential to effectively and safely treat infections.

Forward-looking statements

Statements in this press release containing the words believe, may, expect, project and other similar expressions are forward looking statements that are not definite and have a number of risks and uncertainties. Representative factors that can cause actual results to differ from those projected include the following: regulatory clearance of products, market acceptance; financial constraints; government regulations; obtaining and enforcing intellectual property rights; attracting and retaining key employees; developing partnership opportunities; timing of commercial product launches; and other similar internal and external risks factors.

Media Contact:

Bill Cumbie

144 Research Drive

Hampton, VA 23666

(757) 344-8607

http://www.keraderm.com

bill@keraderm.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Keraderm LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
8. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
9. Immunosyn Corporation Releases SF-1019 Study Results
10. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
11. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, ... Pharmacy released a new white paper to ... use of latex in healthcare. Specifically, there is substantial confusion ... fact, the FDA has urged manufacturers to drop the term ... labels, because of the challenge to ensure a product is ...
(Date:3/28/2017)... ALBANY, New York , March 28, 2017 /PRNewswire/ ... features a largely consolidated vendor landscape, with the top ... and Agilent Technologies accounting for a significant 49% of ... in a recent report. The vendor landscape is intensely ... large share in the overall market. These factors have ...
(Date:3/28/2017)...  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: ... directors: Christopher Gabrieli , ... as chairman of the board of Akcea Therapeutics. ... Forest Laboratories. Sandford D. Smith , ... "We are excited to announce this expansion to our ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: Buying, ... of the webinar will also be made available following its live presentation. The webinar ... still popular targets for healthcare investors. This highly fragmented sector bounced back in 2016, ...
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... suburbs and South Hills of Pittsburgh now have easier access to the ... only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and ...
(Date:3/29/2017)... ... ... has helped over 1.5 million SharePoint users learn the content management system faster and ... for SharePoint was at the farm level. Enterprises using SharePoint Online in Office 365 ... recently released a modified version of the Help System, VisualSP for Site Collections, which ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati ... to directly address the resolution to globally reduce the harmful use of alcohol ... of FDA and TTB approved ingredients that when infused into alcohol, renders the ...
(Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
Breaking Medicine News(10 mins):